ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
62,862.98
-1.37%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) 뉴스

MRK Merck and Co Inc

131.15
0.43 (0.33%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Merck and Co Inc MRK NYSE 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.43 0.33% 131.15 08:26:37
개장가 저가 고가 종가 전일 종가
130.13 130.13 131.91 131.20 130.72
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
26/04/202405:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
25/04/202422:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
25/04/202420:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/04/202419:30BWMerck Announces First-Quarter 2024 Financial Results
19/04/202420:04PRNCASanté Canada approuve KEYTRUDA® comme traitement de première..
10/04/202420:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/04/202419:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/04/202421:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/04/202419:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/03/202419:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/03/202419:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
27/03/202407:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/03/202419:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/03/202422:00BWMerck Announces Positive Data on V116, an Investigational,..
16/03/202405:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/03/202419:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/03/202416:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/03/202421:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
07/03/202400:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/03/202423:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/03/202420:45BWMerck to Participate in the Barclays 26th Annual Global..
04/03/202420:45BWMerck to Participate in the Leerink Partners Global..
27/02/202420:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/02/202420:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
21/02/202406:14EDGAR2Form 8-K - Current report
20/02/202420:45BWFDA Grants Priority Review to Merck's Application for..
16/02/202406:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202406:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/02/202406:40EDGAR2Form 144 - Report of proposed sale of securities
15/02/202406:30EDGAR2Form 144 - Report of proposed sale of securities
15/02/202406:24EDGAR2Form 144 - Report of proposed sale of securities
14/02/202406:50EDGAR2Form 144 - Report of proposed sale of securities
14/02/202406:48EDGAR2Form 144 - Report of proposed sale of securities
13/02/202406:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/02/202421:05PRNCASanté Canada approuve KEYTRUDA®, en association avec le..
10/02/202406:06EDGAR2Form 144 - Report of proposed sale of securities
09/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/02/202421:00PRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE..
08/02/202406:09EDGAR2Form 144 - Report of proposed sale of securities
06/02/202406:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/02/202420:33BWMerck Animal Health to Acquire Elanco’s Aqua Business
03/02/202406:35EDGAR2Form 144 - Report of proposed sale of securities
03/02/202406:09EDGAR2Form 144 - Report of proposed sale of securities
03/02/202406:08EDGAR2Form 144 - Report of proposed sale of securities
03/02/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202406:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/02/202420:39EDGAR2Form 8-K - Current report
01/02/202420:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
28/01/202400:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
27/01/202401:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..

최근 히스토리

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유